References
1. Murayama A, Kamamoto S, Shigeta H, Ozaki A. Industry Payments During
the COVID-19 Pandemic to Cardiologists in the United States. CJC Open
2023;5(3):253-255.
2. Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD,
Hattangadi-Gluth JA. Types and Distribution of Payments From Industry to
Physicians in 2015. JAMA 2017;317(17):1774-1784.
3. Marshall DC, Jackson ME, Hattangadi-Gluth JA. Disclosure of Industry
Payments to Physicians: An Epidemiologic Analysis of Early Data From the
Open Payments Program. Mayo Clin Proc 2016;91(1):84-96.
4. Murayama A. Industry-sponsored meal payments are associated with
prescriptions and Medicare expenditures on brand-name colchicine in the
United States. International Journal of Rheumatic Diseases
2023;n/a(n/a).
5. Murayama A. Pharmaceutical industry-sponsored meals and prescriptions
of biologics for asthma. J Allergy Clin Immunol Pract
2023;11(9):2916-2918.
6. Mitchell AP, Dusetzina SB, Mishra Meza A, Trivedi NU, Bach PB, Winn
AN. Pharmaceutical industry payments and delivery of non-recommended and
low value cancer drugs: population based cohort study. Bmj
2023;383:e075512.
7. Mitchell AP, Trivedi NU, Gennarelli RL, et al. Are Financial Payments
From the Pharmaceutical Industry Associated With Physician Prescribing?
: A Systematic Review. Ann Intern Med 2021;174(3):353-361.
8. Annapureddy AR, Henien S, Wang Y, et al. Association Between Industry
Payments to Physicians and Device Selection in ICD Implantation. Jama
2020;324(17):1755-1764.
9. Yanagisawa M, Blumenthal DM, Kato H, Inoue K, Tsugawa Y. Associations
Between Industry Payments to Physicians for Antiplatelet Drugs and
Utilization of Cardiac Procedures and Stents. J Gen Intern Med
2022;37(7):1626-1633.
10. Medical Governance Research Institute, Tansa. Yen For Docs. Medical
Governance Research Institute; 2023.
11. Murayama A, Saito H, Kamamoto S, Shigeta H, Yamashita E, Tanimoto T,
Ozaki A. Evaluation of non-research payments from pharmaceutical
companies to urologists in Japan between 2016 and 2019. Int Urogynecol J
2023;34(6):1285-1292.
12. Murayama A, Saito H, Tanimoto T, Ozaki A. Financial conflicts of
interest between pharmaceutical companies and executive board members of
internal medicine subspecialty societies in Japan between 2016 and 2020.
J Eval Clin Pract 2023;29(6):883-886.
13. Murayama A, Mamada H, Shigeta H, et al. Financial Relationships
Between Pharmaceutical Companies and Rheumatologists in Japan Between
2016 and 2019. J Clin Rheumatol 2023;29(3):118-125.
14. Murayama A, Hoshi M, Saito H, et al. Nature and Trends in Personal
Payments Made to the Respiratory Physicians by Pharmaceutical Companies
in Japan between 2016 and 2019. Respiration 2022;101(12):1088-1098.
15. Kamamoto S, Ozaki A, Murayama A. Assessment of Financial
Relationships Between Otorhinolaryngologists and Pharmaceutical
Companies in Japan Between 2016 and 2019. Cureus 2023;15(8):e43633.
16. Murayama A, Kamamoto S, Saito H, Ozaki A. Pharmaceutical payments to
Japanese board-certified dermatologists: a 4-year retrospective analysis
of personal payments from pharmaceutical companies between 2016 and
2019. Sci Rep 2023;13(1):7425.
17. Kusumi E, Murayama A, Kamamoto S, et al. Pharmaceutical payments to
Japanese certified hematologists: a retrospective analysis of personal
payments from pharmaceutical companies between 2016 and 2019. Blood
Cancer J 2022;12(4):54.
18. Senoo Y, Saito H, Ozaki A, et al. Pharmaceutical company payments to
authors of the Japanese guidelines for the management of hypertension.
Medicine (Baltimore) 2021;100(12):e24816.
19. Murayama A, Kamamoto S, Kawashima M, Saito H, Yamashita E, Tanimoto
T, Ozaki A. Cross-sectional analysis of pharmaceutical payments to
Japanese board-certified gastroenterologists between 2016 and 2019. BMJ
Open 2023;13(4):e068237.
20. Annapureddy A, Murugiah K, Minges KE, Chui PW, Desai N, Curtis JP.
Industry Payments to Cardiologists. Circ Cardiovasc Qual Outcomes
2018;11(12):e005016.
21. Murayama A, Kamamoto S, Kugo H, Saito H, Ozaki A. Research and
Nonresearch Industry Payments to Nephrologists in the United States
between 2014 and 2021. J Am Soc Nephrol 2023;34(10):1709-1720.
22. Murayama A, Kugo H, Saito Y, Saito H, Tanimoto T, Ozaki A. A 9-Year
Investigation of Healthcare Industry Payments to Pulmonologists in the
United States. Ann Am Thorac Soc 2023;20(9):1283-1292.
23. Kamamoto S, Murayama A, Kusumi E, et al. Evaluation of financial
relationships between Japanese certified pediatric
hematologist/oncologists and pharmaceutical companies: a cross-sectional
analysis of personal payments from pharmaceutical companies between 2016
and 2019. Pediatr Blood Cancer 2022;69(10):e29891.
24. Murayama A, Shigeta H, Kamamoto S, et al. Pharmaceutical Payments to
Japanese Board-Certified Head and Neck Surgeons Between 2016 and 2019.
OTO Open 2023;7(1):e31.
25. Murayama A, Kamamoto S, Saito H, et al. Pharmaceutical Payments to
Japanese Board-Certified Infectious Disease Specialists: A Four-Year
Retrospective Analysis of Payments from 92 Pharmaceutical Companies
between 2016 and 2019. Int J Environ Res Public Health 2022;19(12):7417.
26. Muluk SL, Lin GA, Anderson TS. Association of Device Industry
Payments, Physician Supply, and Regional Utilization of Orthopedic and
Cardiac Procedures. Journal of General Internal Medicine
2023;38(11):2501-2510.
27. Fleischman W, Agrawal S, King M, et al. Association between payments
from manufacturers of pharmaceuticals to physicians and regional
prescribing: cross sectional ecological study. BMJ 2016;354:i4189.
28. Murayama A, Kamamoto S, Murata N, et al. Evaluation of financial
conflicts of interest and quality of evidence in Japanese
gastroenterology clinical practice guidelines. J Gastroenterol Hepatol
2023;38(4):565-573.
29. Mamada H, Murayama A, Ozaki A, et al. Observational study of
financial and non-financial conflicts of interest among the Japanese
government advisory board members concerning coronavirus disease 2019.
Medicine (Baltimore) 2023;102(4):e32776.
30. Murayama A, Yamada K, Yoshida M, et al. Evaluation of Conflicts of
Interest among Participants of the Japanese Nephrology Clinical Practice
Guideline. Clin J Am Soc Nephrol 2022;17(6):819-826.
31. Murayama A, Kamamoto S, Shigeta H, Saito H, Yamashita E, Tanimoto T,
Akihiko O. Undisclosed financial conflicts of interest with
pharmaceutical companies among the authors of the Esophageal Cancer
Practice Guidelines 2017 by the Japan Esophageal Society. Dis Esophagus
2022;35(10).
32. Harada K, Ozaki A, Saito H, et al. Financial payments made by
pharmaceutical companies to the authors of Japanese hematology clinical
practice guidelines between 2016 and 2017. Health Policy
2021;125(3):320-326.
33. Kida F, Murayama A, Saito H, Ozaki A, Shimada Y, Tanimoto T.
Pharmaceutical company payments to authors of the Japanese Clinical
Practice Guidelines for Hepatitis C treatment. Liver Int
2021;41(3):464-469.
34. Hashimoto T, Murayama A, Mamada H, Saito H, Tanimoto T, Ozaki A.
Evaluation of financial conflicts of interest and drug statements in the
coronavirus disease 2019 clinical practice guideline in Japan. Clin
Microbiol Infect 2022;28(3):460-462.
35. Murayama A, Ozaki A, Saito H, Sawano T, Sah R, Tanimoto T.
Coronavirus disease 2019 experts appearing on Japanese television: their
characteristics and financial conflicts of interest with pharmaceutical
companies. Clin Microbiol Infect 2020;27(5):805-807.
36. Murayama A. Financial Conflicts of Interest Among the Authors of the
Clinical Practice Guidelines for Rheumatoid Arthritis in Japan. Cureus
2023;15(10):e46650.
37. Mamada H, Murayama A, Kamamoto S, et al. Evaluation of Financial and
Nonfinancial Conflicts of Interest and Quality of Evidence Underlying
Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal
Payments From Pharmaceutical Companies and Authors’ Self-Citation Rate
in Japan and the United States. Arthritis Care Res (Hoboken)
2023;75(6):1278-1286.
Table 1. Summary of personal payments to board-certified cardiologists